Oral baclofen has long been a mainstay in the management of spasticity. This review looks at the clinical evidence for the efficacy and safety of oral baclofen in patients with spasticity of any origin or severity, to determine whether there is a rationale for the use of intrathecal baclofen. Results suggest that oral baclofen may be effective in many patients with spasticity, regardless of the underlying disease or severity, and that it is at least comparable with other antispasmodic agents. However, adverse effects, such as muscle weakness, nausea, somnolence and paraesthesia, are common with oral baclofen, affecting between 25% and 75% of patients, and limiting its usefulness. Intrathecal baclofen may be an effective alternative as the drug is delivered directly into the cerebrospinal fluid, thus bypassing the blood-brain barrier and thereby optimizing the efficacy of baclofen while minimizing drug-related side-effects. Intrathecal baclofen is a viable option in patients who experience intolerable side-effects or who fail to respond to the maximum recommended dose of oral baclofen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/16501977-2211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacovigilance insights into medication-induced risk of dural arteriovenous fistula.
Int J Surg
January 2025
Department of Orthopedics, Civil Aviation General Hospital, Beijing, China.
Background: Dural arteriovenous fistulas (DAVFs) pose a significant health threat owing to their high misdiagnosis rate. Case reports suggest that DAVFs or related acute events may follow medication use; however, drug-related risk factors remain unclear. In clinical practice, the concomitant use of multiple drugs for therapy is known as "polypharmacy situations," further increasing the risk of drug-induced DAVF.
View Article and Find Full Text PDFPost-Stroke Spasticity Treatment: A Retrospective Cohort Study From Alberta, Canada.
Can J Neurol Sci
November 2024
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Article Synopsis
- A retrospective cohort study analyzed post-stroke spasticity (PSS) treatment data from Alberta, Canada, focusing on patients who started PSS treatment between 2012 and 2019.
- The most common treatment was oral baclofen, prescribed mainly by primary care physicians, with a median start time of 348 days after the stroke.
- The study highlighted issues such as over-reliance on oral baclofen (which has side effects) and underutilization of focal botulinum toxin injections, indicating a need for better alignment with treatment guidelines to improve patient outcomes.
Baclofen-related deaths in Australia 2000-2022.
Forensic Sci Int
December 2024
National Drug & Alcohol Research Centre, University of New South Wales, NSW 2052, Australia.
Article Synopsis
- Baclofen, prescribed for muscle spasms in Australia, has been linked to 102 deaths from 2000-2022, with a majority involving intentional toxicity and a significant presence of mental health and substance use issues among victims.
- The average age of those who died was about 45.6 years, with 51% being male, and 73.5% had documented mental health problems.
- The study highlights the importance of caution in prescribing baclofen due to its potential for misuse, dependency, and overdose.
Replacing hospital nurse consultations with home-based nurse consultations for severe spasticity patients on intrathecal baclofen: a qualitative study.
Disabil Rehabil
October 2024
Department of Oral and Maxillofacial Surgery, Odense University Hospital, Odense, Denmark.
Aim: This qualitative study explored the experiences of patients, caregivers and healthcare professionals after replacing hospital consultations with a home service solution for patients treated for severe spasticity with intrathecal baclofen.
Method: Semi-structured interviews were conducted with six patients, six caregivers and six healthcare professionals. The data were analysed using interpretative phenomenological analysis.
A Retrospective Analysis of Medical Management Strategies for Trigeminal Neuralgia: An Institutional Review.
Cureus
September 2024
Oral Pathology and Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Article Synopsis
- Trigeminal neuralgia (TN) is a painful disorder affecting the trigeminal nerve, causing severe facial pain and often requiring treatments like medications or surgical procedures when drugs are ineffective.
- This study analyzed 483 TN cases over five years to understand patient demographics, focusing on age, gender, and which divisions of the trigeminal nerve were most affected.
- Results showed that the average patient age was around 60 years, with the majority experiencing pain on the right side of the face, primarily affecting the maxillary (V2) and mandibular (V3) nerve divisions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!